BlackRock Posts Mixed Q3 Earnings; Bullish View On Immunovant
- October 13th, 2023
- 805 views
BlackRock, Inc. (NYSE: BLK), an investment management and financial services company, reported third-quarter 2023 adjusted earnings per share (EPS) of $10.91, surpassing the consensus EPS estimate of $8.26. However, the company's revenue for the period stood at $4.522 billion, slightly below analysts' expectations of $4.54 billion.
$BLK was trading at $630.00 in pre-market, reflecting a decrease of $6.17 (-0.97%).
In other news, UBS has upgraded Immunovant, Inc. (Nasdaq: IMVT), a biopharmaceutical company, from Neutral to Buy and raised the price target from $18 to $55.
Despite closing at $35.28 on Thursday, the adjusted price target indicates a potential upside of $19.72 or about 55.86% for $IMVT, based on the financial services firm's analysis
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
September 23rd, 2026
FTC Endorses Education Department Proposal to Expand Higher Education Accreditation Options
September 22nd, 2026September 18th, 2026FTC Takes Action to Prevent Anticompetitive Arrangement in Beretta, Ruger Deal
September 16th, 2026Why Opponent Preparation Matters for Post-Graduate Athletes
September 16th, 2026
Member Login